SET Antibody, FITC conjugated

Cusabio

SET Antibody, FITC conjugated

20

Research Use Only

Polyclonal

FITC

SET

SET nuclear proto-oncogene

2PP2A, I2PP2A, IGAAD, IPP2A2, MRD58, PHAPII, TAF-I, TAF-IBETA, protein SET, HLA-DR-associated protein II, SET nuclear oncogene, SET translocation (myeloid leukemia-associated), Template-Activating Factor-I, chromatin remodelling factor, chromatin remodelling factor, inhibitor of granzyme A-activated DNase, inhibitor-2 of protein phosphatase-2A, phosphatase 2A inhibitor I2PP2A, protein phosphatase type 2A inhibitor

Rabbit

IgG

Protein SET

Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone chaperoning. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher.

Human

-20°C or -80°C

41116161